Recent News & Press

  • CATEGORY Press
Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
READ MORE
  • CATEGORY News
Dec 1st Nature article: Sticking the landing: covalency comes to radioligand therapy
READ MORE
  • CATEGORY Press
Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications
READ MORE
  • CATEGORY Press
Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
READ MORE
  • CATEGORY Press
Covalent Radioligands Advance Precision in Tumor Targeting – Andreas Goutopoulos
READ MORE
Linkedin